Skip to main content

Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor

Abstract

Although the Sokal and Hasford scoring systems are well-known prognostic models specific to chronic myeloid leukemia (CML), whether they can effectively predict outcomes in elderly CML patients with comorbidities has not been fully elucidated. We evaluated the association between comorbidity at diagnosis with treatment outcome and survival in chronic phase CML patients. A questionnaire was administered to patients diagnosed with CML between 2001 and 2012 and treated with tyrosine kinase inhibitors (TKIs). The Charlson comorbidity index (CCI) was used to determine concomitant diseases. In total, 79 patients (33 females; median age, 57 years) were enrolled. CCI scores at diagnosis were between 2 and 11. At the last follow-up, 46 patients showed a major molecular response. Complete cytogenetic response was achieved in 73.4 % of the cases 12 months after TKI administration. We observed only five deaths during the 55.5-month median follow-up period. The risk categories (low/intermediate/high) associated with Sokal and Hasford scores were 33/27/7 and 21/43/3, respectively. The 27 cases with a CCI score >3 had significantly poorer survival after diagnosis (52 cases had a CCI score <2). CCI scores were inversely associated to overall survival. Concomitant comorbidity at diagnosis is associated with poor outcome in CML patients treated with TKIs.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012;120:1390–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Höglund M, Sandin F, Hellström K, Björeman M, Björkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122:1284–92.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–61.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.

    CAS  PubMed  Google Scholar 

  6. 6.

    Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon AlfaWriting Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850–8.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal’s index and a new score. German chronic myeloid leukaemia (CML)-Study Group. Br J Haematol. 1997;97:76–85.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686–92.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica. 2011;96:1457–61.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Saika K, et al. Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the US. Oncologist. 2012;17:1547–50.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al. Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126:42–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808–17.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, et al. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105:105–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Iriyama N, Hatta Y, Kobayashi S, Uchino Y, Miura K, Kurita D, et al. The European Treatment and outcome study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia. Int J Hematol. 2014;100:379–85.

    Article  PubMed  Google Scholar 

  18. 18.

    Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, Cartoni C, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol. 2009;27:148–53.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Osamu Imataki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

M. Uemura and O. Imataki contributed equally to this work.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Uemura, M., Imataki, O., Kawachi, Y. et al. Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor. Int J Hematol 104, 621–627 (2016). https://doi.org/10.1007/s12185-016-2074-3

Download citation

Keywords

  • Chronic myeloid leukemia
  • Tyrosine kinase inhibitor
  • Charlson comorbidity index
  • Sokal score
  • Hasford score